(Q46866125)

English

Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results

scientific article published on 12 December 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/22162539

0 references

Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results (English)

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/22162539

1 reference

ChEBI release 2020-05-28

author name string

John P Gibbs

1

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/22162539

Jill Fredrickson

2

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/22162539

Todd Barbee

3

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/22162539

Itzela Correa

4

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/22162539

Brian Smith

5

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/22162539

Shao-Lee Lin

6

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/22162539

Megan A Gibbs

7

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/22162539

publication date

12 December 2011

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/22162539

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/22162539

52

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/22162539

10

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/22162539

1494-1505

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/22162539

Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Unraveling the science of incretin biology

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

The biology of incretin hormones

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Incretin-based therapies: review of current clinical trial data.

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared wi

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Model-based drug development

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain--results of a model-based meta-analysis that accounts for encapsulation

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Model-based development of gemcabene, a new lipid-altering agent

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

A model-based meta-analysis of the effect of latanoprost chronotherapy on the circadian intraocular pressure of patients with glaucoma or ocular hypertension

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Model-based development of a PPARgamma agonist, rivoglitazone, to aid dose selection and optimize clinical trial designs

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Dopamine D(2) receptor blockade in schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Evaluation of structural models to describe the effect of placebo upon the time course of major depressive disorder

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlation

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Pharmacokinetics and Pharmacodynamics of Vildagliptin??in??Patients?? with Type??2??Diabetes??Mellitus

1 reference

https://api.crossref.org/works/10.1177%2F0091270011420153

21 January 2018

Identifiers

10.1177/0091270011420153

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/22162539

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/22162539

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46866125&oldid=2135312867"